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Interleukin-22 ameliorates liver 
fibrosis through miR-200a/beta-
catenin
Bang-li Hu1,*, Cheng Shi1,*, Rong-e Lei1, Dong-hong Lu1, Wei Luo1, Shan-yu Qin1, You Zhou2 & 
Hai-xing Jiang1
IL-22 ameliorates liver fibrosis by inhibiting hepatic stellate cells (HSC), and loss of miR-200a is 
associated with the development of liver fibrosis. The study aimed to investigate the interplay between 
IL-22 and miR-200a in regulating liver fibrosis in vivo and in vitro. We observed that IL-22 significantly 
reduced the proliferation of HSC and increased the expression of p-STAT3. β-catenin was identified 
as a target gene of miR-200a by luciferase reporter assay, and upregulation of miR-200a significantly 
attenuated the proliferation of HSC and reduced β-catenin expression. IL-22 treatment increased 
expression of miR-200a and decreased expression of β-catenin in HSC. The expression of p-STAT3 
and miR-200a was elevated while β-catenin was decreased in fibrotic rat liver after IL-22 treatment. 
Expression levels of β-catenin and p-STAT3 were inversely correlated in fibrotic rat liver and HSC. 
Upregulation of β-catenin suppressed expression of p-STAT3 in HSC. We concluded that IL-22 inhibits 
HSC activation and ameliorates liver fibrosis through enhancing expression of miR-200a and reducing 
expression of β-catenin, suggesting there may be a crosstalk between IL-22/STAT3 and β-catenin 
pathway.
Liver fibrosis, a primary consequence of chronic liver injury, is characterized by activation of hepatic stellate 
cells (HSC) and accumulation of extracellular matrix and collagen protein. It has been suggested that inhibiting 
HSC activation is an important strategy for the treatment of liver fibrosis1,2. The pathogenesis of liver fibrosis is 
regulated by a variety of inflammatory cytokines. Interleukin-22 (IL-22), a critical immune mediator, has been 
reported to ameliorate liver fibrogenesis in mice by inducing the senescence of HSCs3. Moreover, our study also 
showed that treatment with IL-22 accelerated the resolution of liver fibrosis in mice4.
MicroRNAs (miRNAs) are short, non-coding RNA molecules that regulate gene expression via mRNA dead-
enylation or destabilization and translational repression or activation. miRNAs regulate a variety of cellular pro-
cesses including cell proliferation, differentiation, invasion, migration, and epithelial-mesenchymal transition5. 
Increasing evidence shows a few miRNAs act as important regulators in the pathogenesis of liver fibrosis6,7. It has 
been recently reported that increasing expression of miRNA-200a attenuates HSC proliferation while knocking 
down miR-200a prompted HSC proliferation8,9.
Both IL-22 and miRNA-200a alleviate the pathogenesis of liver fibrosis. However, whether there is any cross-
talk between IL-22 and miRNA-200a in anti-fibrotic effects remains unknown. In the present study, we searched 
potential target of miR-200a and explored the mechanism of IL-22 and miR-200a in inhibiting HSC activity. 
We further examined the regulatory role of IL-22 in the expression of miR-200a and its target in a HSC cell line, 
primary HSCs and a rat model of liver fibrosis. Our results reveal the interaction between IL-22 and miR-200a in 
regulating the development of hepatic fibrosis.
Material and Methods
Animals and treatments. The study protocol was approved by the ethics committee of the First Affiliated 
Hospital of Guangxi Medical University. All experimental procedures on rats were approved by the ethics com-
mittee of Animal Experiments of Guangxi Medical University. The study was carried out in accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. 
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Normal male Sprague–Dawley rats (100–120 g) were obtained from Laboratory Animal Center (Guangxi Medical 
University, China, N.O. SCXKG 2010-0002). Animals were kept in the pathogen-free animal room (12 hours 
light/12 hours dark; temperature, 22–24 °C), and received water ad libitumin in the Animal Care Facility Service 
(Guangxi Medical University, China).
Administration with recombinant IL-22 protein. To induce the liver fibrosis, rats were intraperitone-
ally (IP) injected with 1 mL/kg body weight of 50% CCl4 in olive oil 2 times weekly for 8 weeks. After this, mice 
(n = 10) were injected IP with 0.3 μ g/g body weight of recombinant rat interleukin-22 (rrIL-22) (R&D Systems, 
Inc., Minneapolis, USA) once per week for 2 weeks. Mice (n = 10) administered with 0.5% BSA in PBS were used 
as controls.
Knocking-down miR-200a. To knock down the expression of miR-200a, rats with liver fibrosis (n = 10) 
were hydrodynamicaly tail vein injected with lent-miR-200a inhibitors (1 × 108 TU/mL) in PBS for 1 week. After 
this, rats were IP injected with 0.3 μ g/g body weight of rrIL-22 once per week for 2 weeks. After the scarification, 
the liver tissues were collected and fixed in 10% neutral buffered formalin for hematoxylin and eosin (H&E) 
staining and Masson staining.
Histology and immunohistochemistry. Slices of tissue were prepared in 4 μ m thickness and stained with 
H&E and Masson staining according to standard procedures. Two experienced pathologists assessed liver histol-
ogy blindly by using light microscopy (Nikon Eclipse E800 Microscope, Kawasaki, Kanagawa, Japan). For immu-
nohistochemistry, the sections were incubated with primary antibody of α -SMA (1:300 dilution, Sigma-Aldrich), 
followed by incubation with streptavidin-peroxidase complex. Peroxidase conjugates were subsequently visual-
ized using diaminobenzidine solution. The sections were then counterstained with hematoxylin and mounted on 
a cover slip. Evaluation of liver fibrosis was using Ishak  fibrosis score.
Cell culture. The rat HSC (HSC-T6) was purchased from ATCC and cultured in Dulbecco’s modified Eagle 
medium (DMEM) (Gibco, USA) supplemented with 10% fetal bovine serum (Gibco), 100 U/ml penicillin, and 
100 mg/ml streptomycin. Primary rat HSCs were isolated from rat livers by pronase/collagenase digestion as 
previously described10. For each experiment, primary HSCs from 3 donor rats were used. HSC-T6 and primary 
HSCs were incubated with 5 ng/mL TGF-β 1 in PBS buffer (R&D Systems, Inc., Minneapolis, USA) for 48 h for 
activation11.
RNA extraction and quantitative real-time PCR (qRT-PCR). miR-200a was isolated from cells or 
homogenized liver tissues using miRVana miRNA isolation kit (Takara, Dalian, China). Real time PCR assays 
were performed using PrimeScriptTM RT reagent Kits (TaKaRa), SYBR Green® miRcute miRNA Realtime PCR 
Kit (Tiangen, Beijing, China), SYBR Green® Realtime PCR Master Mix and Permix Ex Taq (TaKaRa) according 
to the manufacturer’s instructions.
Primers used were as follows: rat β -catenin, (Forward) 5′ -CTT ACG GCA ATC AGG AAA GC-3′ and 
(Reverse) 5′ -GAC AGA CAG CAC CTT CAG C-3′ ; GAPDH, (Forward) 5′ -CGG ATT TGG TCG TAT TG-3′ 
and (Reverse) 5′ -GAA GAT GGT GAT GGG ATT-3′ . Primers for U6 and miR-200a were purchased from Sangon 
Biotech (Shanghai, China). The relative gene expression was normalized to the level of GAPDH while expression 
of miR-200a was normalized to the level of U6. All reactions were performed in triplicates for each sample. At 
least three independent experiments were carried out for each experimental condition.
Enzyme linked immunosorbent assay (ELISA). The cell culture supernatant was collected after 48 h 
culture. The concentrations of α -SMA and type I collagen (Col I) in the supernatant were measured using a 
ELISA kit (Cusabio, Wuhan, China) according to the manufacturer’s instructions. The optical density of the 
microplate was determined at 450 nm.
Western blot analysis. After treatment with IL-22 for 48 h, the protein was extracted from cell lysates in the 
lysis buffer containing protease inhibitors and phosphatase inhibitors (Sigma, USA). The concentration of cellular 
protein was determined by the Pierce BCA assay (Thermo Fisher Scientific, Rockford, USA). Total protein extracts 
were separated by electrophoresis for 90 min and transferred onto a polyvinylidene fluoride membrane (Merck 
Millipore, USA). The primary antibodies used were rabbit anti-STAT3 (1:3000, Abcam, UK), anti-p-STAT3 pri-
mary antibody (1:2000, Abcam) and anti-β -catenin (1:2000, Abcam). LI-COR IRDye 680-labeled secondary 
antibody was used (Rockland Immunochemical, Gilbertsville, PA). The signals were detected and quantified by 
using Odyssey Infrared Imaging System (Li-COR Biosciences, Lincoln, NE) and Fluorchem 8900 system (Alpha 
Innotech, San Leandro, CA).
Overexpression and knock down miR-200a in HSC. To overexpress and knock down miR-200a, lenti-
viruses of rno-miR-200a mimics, miR-200a inhibitors and a non-specific control were transduced into HSC cells 
(Genepharma, Shanghai, China). The sequences were as follows: miRNA-200a mimic sense 5′ -UAA CAC UGU 
CUG GUA ACG AUG U-3′ and anti-sense 5′ -ACA UCG UUA CC A GAC AGU GUU A-3′ , and miRNA-200a 
inhibitor sequences were 5′ -ACA UCG UUA CCA GAC AGU GUU A-3′ . After transduction with rno-miR-200a 
lentivirus for 72 h, cells were monitored under immunofluorescence microscopy to ensure at least 80% of the cells 
expressed green fluorescence protein (GFP). qRT-PCR was used to detect the expression of miR-200a.
Cell proliferation and apoptosis assay. The Cell Counting Kit-8 (CCK-8, Dojindo, Beijing, China) 
assay was used as a qualitative index of cell proliferation according to the manufacturer’s instructions. Apoptotic 
cells were quantified using FITC Annexin V Apoptosis Detection Kit (BD Biosciences, Vienna, Austria) 
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according to the manufacturer’s instructions. Cell analyses were performed by BD FACSCalibur flow cytometer 
(BD Biosciences). The apoptotic cells were defined as Annexin- V-positive cells. Each experiment was repeated 
three times independently.
Figure 1. IL-22 inhibited HSC proliferation via STAT3 pathway. (A) IL-22 significantly inhibited 
proliferation of HSC; (B) No significantly change of apoptosis of HSC after IL-22 treatment. (C,D) 
Protein expression of STAT3 and phosphorylated STAT (p-STAT3) in HSC after treatments with different 
concentrations of IL-22. (n = 3). *p < 0.05.
Figure 2. Expression of miR-200a and β-catenin was decreased during HSC activation. (A) Expression of 
miR-200a in HSC was decreased after treatment with TGF-β 1; (B) Expression of β -catenin mRNA in HSC was 
increased after treatment with TGF-β 1; (C,D) Western blotting indicated that β -catenin protein levels were 
increased in HSC after treatment with TGF-β 1. (n = 3). *p < 0.05.
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Luciferase reporter assay. The sequences of β -catenin 3′ -UTR containing the predicted miR-200a binding 
sites were cloned into psiCHECK2 (C8021, Promega, USA). The constructs were transfected into HEK293 cells 
together with miR-200a or miR-200a inhibitors by using Lipofectamine 2000 (Invitrogen). After transfection for 
48 h, the Renilla and Firefly luciferase activities were measured by the Dual-Luciferase Reporter Assay (Promega, 
Madison, WI, USA) with a luminometer (SynergyTM 4 Hybrid Microplate Reader, BioTek, USA). The luciferase 
activity values were normalized using the Renilla values.
Bioinformatic analyses. Three algorithms (TargetScan, Diana-microT and miRWalk) were used to predict 
miRNA targets. We restricted miRNA binding sites to the 3′ UTR region. The minimum seed length for miRNA 
binding was 7 nucleotides.
Statistical analysis. All data were analyzed using SPSS 16.0 software (SPSS Inc, Chicago, IL, USA). Data 
were expressed as means ± standard deviation (SD). Two group comparisons were carried out using Student’s t 
test or Mann–Whitney U test when appropriated. The differences among multiple groups were compared using 
one-way analysis of variance (ANOVA) followed by LSD post-hoc test. A two-sided p value of less than 0.05 indi-
cated statistical significance.
Results
IL-22 suppressed HSC proliferation. HSC-T6 and primary HSC were incubated with recombinant IL-22 
protein at concentrations of 250, 500, 750 and 1000 pg/mL respectively for 48 h. Treatment with higher con-
centration of IL-22 protein showed stronger inhibitory effect on the proliferation of HSC cell line and primary 
HSC (Fig. 1A). In contrast, the apoptosis rate of HSC did not change significantly in response to incubation with 
Figure 3. miR-200a inhibited proliferation of HSC. (A) Transfection with miR-200a mimics suppressed HSC 
proliferation; (B) No change of HSC apoptosis after transfection with miR-200a mimics. (n = 3). *p < 0.05.
Figure 4. miR-200a targeting β-catenin in HSC. (A) The predicted miR-200a binding site at the 3′ -UTR of  
β -catenin mRNA; (B) Luciferase reporter assay revealed that β -catenin is a target of miR-200a; (C,D) Western-
blot indicated that miR-200a significantly decreased protein expression of β -catenin. (n = 3). **p < 0.01.
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different concentrations of IL-22 protein (Fig. 1B). Treatment with either 750 or 1000 pg/mL IL-22 significantly 
induced expression of phosphorylated STAT (p-STAT3) but not STAT3 (Fig. 1C,D).
Expression of miR-200a and β-catenin after HSC activation. HSC-T6 and primary HSC were acti-
vated by incubation with 5 ng/mL TGF-β 1 for 48 h. After HSC activation, expression of miR-200a remarkably 
decreased (Fig. 2A), while expression of β -catenin significantly increased in mRNA (Fig. 2B) and protein levels 
(Fig. 2C,D).
miR-200a inhibited HSC proliferation. Since HSC activation suppressed expression of miR-200a, we 
further overexpressed miR-200a with a lentiviral vector in HSC and measured its effect on proliferation and apop-
tosis. We found that overexpression of miR-200a inhibited not only HSC-T6 but also primary HSC proliferation 
(Fig. 3A). However, the overexpression had no effect on the apoptosis of HSC-T6 and primary HSC (Fig. 3B). 
Collectively, these results suggested an inhibitory role of miR-200a in HSC proliferation.
β-catenin was a downstream target of miR-200a. Target prediction for miR-200a suggested that it reg-
ulates the expression of β -catenin through a potential seed region in 3′ UTR (Fig. 4A). To confirm that β -catenin 
is a direct target of miR-200a, we obtained luciferase-3′ UTR reporter constructs for the mRNA and transfected 
them into HEK293T cells together with miR-200a mimics or a non-targeting control miRNA. Transfection with 
miR-200a significantly reduced firefly luciferase activity for β -catenin (p < 0.01, Fig. 4B) compared to the negative 
control. 3′ UTR mutagenesis of sequence complementary to the miR-200a seed region attenuated miRNA effect 
(Fig. 4C,D), suggesting that β -catenin is a directly regulated by miR-200a in HSC.
Figure 5. IL-22 inhibited HSC activation via regulation of miR-200a/β-catenin. (A) Proliferation of 
HSC after treatment with IL-22, TGF-β 1 or the combination; (B,C) Expression of α -SMA and Col I in the 
supernatant; (D) Expression of miR-200a in HSC; (E–G): Expression of β -catenin mRNA and protein in 
HSC; (H) Proliferation of HSC after treatment with IL-22, miR-200a inhibitors or the combination; (I–K) 
Expression of β -catenin mRNA and protein in HSC after treatment with IL-22, miR-200a inhibitors or the 
combination. (one-way ANOVA/LSD post-hoc test, n = 3). *p < 0.05.
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IL-22 inhibited HSC activity via regulation of miR-200a. Primary HSC cells pre-incubated with 
TGF-β 1 for 24 h and subsequently cultured with 1.5 ng/mL IL-22 for 48 h. For activated HSC cells, treatment with 
IL-22 significantly inhibited HSC proliferation (Fig. 5A) and suppressed mRNA levels of α -SMA and Col I in the 
supernatant (Fig. 5B,C), Of note, treatment with IL-22 induced mRNA expression of miR-200a (Fig. 5D) and 
decreased mRNA and protein levels of β -catenin in the activated HSC cells (Fig. 5E–G).
In order to explore the relationship between IL-22 and miR-200a in HSC activity, we knocked down miR-200a 
in HSC cells using its inhibitors, subsequently treated cells with IL-22 protein and measured cell proliferation, 
mRNA and protein expression. The proliferation of HSC was increased and then compared to that without miR-
200a inhibitors transfection (Fig. 5H), and the expression of β -catenin increased significantly (Fig. 5I–K). Taken 
together, these results indicated that IL-22 inhibited HSC activity through the regulation of miR-200a/β -catenin.
IL-22 alleviated liver fibrosis and increased miR-200a expression in rat. To further elucidate the 
relationship between IL-22 and miR-200a in liver fibrosis, a fibrotic rat model was IP injected with rrIL-22. We 
observed that fibrotic status was alleviated after rrIL-22 treatment compared with controls (Fig. 6A). Moreover, 
IL-22 treatment induced expression levels of miR-200a (Fig. 6B) and reduced mRNA and protein expression of 
β -catenin in rat fibrotic liver compared with controls (Fig. 6C,D). Furthermore, we found expression levels of 
p-STAT3 significantly increased upon IL-22 treatment while STAT3 not (Fig. 6E,F).
Effect of IL-22 on liver fibrosis was reduced by miR-200a inhibitor transfection. The expres-
sion levels of miR-200a in rat fibrotic liver significantly decreased in the group treated with miR-200a inhibitor 
Figure 6. IL-22 alleviated liver fibrosis and increased miR-200a expression in rat. (A) Change of liver tissue 
of rat with liver fibrosis with or without IL-22 treatment. (B) Expression of miR-200a in liver tissue with or 
without IL-22 treatment; (C,D) Expression of β -catenin in liver tissue with or without IL-22 treatment;  
(E,F) Expression of STAT3 in liver tissue with or without IL-22 treatment. (n = 5). *p < 0.05, **p < 0.01.
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injection compared with PBS group and IL-22 + miR-200a inhibtors group (Fig. 7A). Similar to the results of 
expression of miR-200a, we found that the liver fibrosis recovery slower after miR-200a inhibitor injection com-
pared with PBS group and the IL-22 + miR-200a inhibitor group according to the Ishak fibrosis score (Fig. 7B). 
We also observed that the expression of p-STAT3 was increased in the group of miR-200a inhibitor injection com-
pared with PBS group and IL-22 + miR-200a inhibitors group (Fig. 7C,D). Collectively, these results suggested 
that miR-200a was involved in the regulatory function of IL-22 in alleviating liver fibrosis.
Interaction of β-catenin and STAT3 in HSC. Expression of p-STAT3 significantly increased while 
β -catenin decreased along with the treatment with IL-22 concentration from low to high concentrations in HSC. 
The protein concentrations of p-STAT3 was inversely correlated that of β -catenin (P = 0.014, Fig. 8A).
Using miR-200a mimics to transfect HSC, we found that the expression of p-STAT3 was increased in HSC 
with the overexpression of miR-200a, which was contrast to the expression of β -catenin, and transfection of miR-
200a inhibitors in HSC resulted in decreased of p-STAT3 and increased of β -catenin ( Fig. 8B).
Figure 7. Effect of IL-22 on liver fibrosis was reduced by miR-200a inhibitor transfection. (A) Expression 
of miR-200a in rat fibrotic liver tissue in the PBS group, IL-22 + miR-200a inhibitors group and miR-200a 
inhibitors group; (B) Ishak fibrosis score in rat fibrotic liver tissue in the PBS group, IL-22 + miR-200a inhibitors 
group and miR-200a inhibitors group; (C,D) Expression of STAT3 and p-STAT3 proteins in fibrotic rat liver 
tissue in the PBS group, IL-22 + miR-200a inhibitors group and miR-200a inhibitors group. (one-way ANOVA/
LSD post-hoc test, n = 5). *p < 0.05, **p < 0.01.
Figure 8. β-catenin and STAT3 protein expression in response to miR-200a in HSC. (A) Correlation analysis 
of p-STAT3 and β -catenin after treatment with IL-22 in HSC; (B) Comparisons of STAT3 and β -catenin protein 
levels in HSC after miR-200a mimics or miR-200a inhibitors transfection. (n = 3). *p < 0.05, **p < 0.01.
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Discussion
IL-22, a member of IL-10 cytokine family, is produced by Th17, Th22 cells12 and activated NK and NKT cells13. 
IL-22 exerts its cellular effects via a heterodimeric transmembrane receptor formed by IL-10R2 and IL-22R114, 
subsequently activates Janus kinase-signal transducers and activators of transcription molecules including 
STAT3, Jak1 and Tyk215. To date, several studies reported potential effects of IL-22 on liver fibrosis; however, the 
mechanism of IL-22 in liver fibrogenesis remains unclear16,17.
In agreement with previous reports3,4, our data showed that treatment with IL-22 significantly inhibited devel-
opment of liver fibrosis. Moreover, similar to the Kong et al.3 report, we found that inhibitory effect of IL-22 on 
HSC was majorly reflected by suppression of cell proliferation rather than apoptosis, and reduction of cytokines, 
α -SMA and Col. We further observed that STAT3 pathway was activated along with the treatment, indicating that 
IL-22 may inhibit HSC proliferation through STAT3 pathway. It was reported that STAT3 activation in response 
to IL-22 induces HSC senescence and subsequently inhibits HSC proliferation3. Moreover, IL-22/STAT3 has an 
anti-fibrotic function in T cell-mediated murine hepatitis. Radaeva et al.18 showed that IL-22 blockade reduced 
STAT3 activation and exacerbated liver injury in T cell-mediated hepatitis, whereas injection of IL-22 attenuates 
the injury. Blocking STAT3 activation abolishes the antiapoptotic and mitogenic actions of IL-22 in hepatic cells.
To date, a few miRNAs have profound role in the development of liver fibrosis. The miRNA-200 family was 
reported to be an important one in liver fibrogenesis19,20. A recent study showed that miRNA-200a silencing 
activated HSC through Keap1, while overexpression of miRNA-200a inhibited HSC proliferation8. Consistent 
with Yang et al.8 study, we found that expression of miRNA-200a was reduced in the activated HSC as well as in 
fibrotic rat liver tissues compared with controls, suggesting that loss of miRNA-200a induces development of liver 
fibrosis.
β -catenin, a component of adhering junctions, is necessary for cadherin–catenin interaction21. As a key sign-
aling effector in the Wnt signaling pathway, β -catenin is involved in the cell survival, proliferation, migration and 
polarity22. Several studies reported that β -catenin was overexpressed in human tissues with liver fibrosis while 
blockage of Wnt/β -catenin pathway inhibited HSC activation23–26. Our study identified β -catenin as a direct target 
of miRNA-200a, suggesting that miRNA-200a exerts its anti-fibrotic effects via directly down-regulated β -catenin 
expression.
Liver fibrogenesis consists a number of critical pathways that may interact together as functional partners. For 
example, interaction between Notch Hedgehog pathways controls the cell fate and mediates liver repair in vivo27. 
Cross-talk between TGF-β 1 and epidermal growth factor receptor signaling pathways induces TM4SF5 expres-
sion and epithelial-mesenchymal transition28. Our study showed treatment with IL-22 induced the expression of 
miR-200a, decreased β -catenin in HSC and rat fibrotic liver tissues via STAT3 pathway. We further identified the 
inverse association between expression of STAT3 and β -catenin in HSC, indicating there may have a cross-talk 
between IL-22/STAT3 and Wnt/β -catenin signaling pathways in development of liver fibrosis. Further study is 
warranted in understanding how these two pathways are connected.
In conclusion, our results demonstrate that IL-22/STAT3 regulates HSC activation and ameliorates liver 
fibrosis through modulating expression of miR-200a and β -catenin. The interaction between IL-22/STAT3 and 
Wnt/β -catenin pathway is involved in the development of hepatic fibrosis in vivo. These results might help in 
developing more effective therapy for liver fibrosis.
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